INVESTORSADVISORSCONTACT US

Investors

Investors

 
 

On July 26, 2019 KBL Merger Corp. IV (NASDAQ: KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC) executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with 180 Life Sciences (formerly known as CannBioRx Life Sciences Corp.).

Visit www.kblmerger.com

Pursuant to the agreement, the stockholders of 180 will receive, in the aggregate, a number of shares of KBLM based on a pre-money valuation of $175 million (with deductions for liabilities existing at the closing of the transaction in excess of $5 million divided by 10).

KBLM and 180 are finalising their final proposal to the SEC ahead of closing.

Read the press releases concerning the merger here